

IN THE U.S. PATENT AND TRADEMARK OFFICE

M. Vijay Kumar

Appl. No.:

10/077,435

Art Unit:

1642

Filed:

February 15, 2002

Examiner:

Davis, Minh Tam B

For:

TREATMENT OF PROSTATE CANCER

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98, applicant(s) hereby submit(s) an Supplemental Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO/SB/08A(s), attached hereto.

II. **COPIES** (check at least one box)

a.	This	application	was	filed	before	June	30,	2003.	Accordin	ngly,
	subm	itted herewith	h is a	legible	copy of	(i) ea	ch U.	S. and f	foreign pa	tent;
	(ii) e	ach publicati	on or	that p	ortion v	vhich o	cause	d it to	be listed;	and
	(iii) a	ll other infor	matio	n or tha	at portion	n whic	h cau	ised it to	o be listed	

b.	\boxtimes	This application was filed on or after June 30, 2003. Accordingly,
		copies of cited U.S. patents and patent application publications
		therefore are not included. Copies of foreign patent documents and
		non-patent literature are included.

	c.		Some or all of the documents listed on the PTO/SB/08A are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.
III.			XPLANATION OF THE RELEVANCE st one box)
	a.	\boxtimes	DOCUMENTS IN THE ENGLISH LANGUAGE
			The patents, publications, or other information listed on the attached PTO/SB/08A are in the English language and therefore, do not require a statement of relevancy.
	b.		DOCUMENTS NOT IN THE ENGLISH LANGUAGE
			A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:
	c.		ENGLISH LANGUAGE SEARCH REPORT
			An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).
	d.		OTHER
			The following additional information is provided for the Examiner's consideration.

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b): (check one box)				
	a.		within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. (This section is not to be used with RCE's.)	
	b.		within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.	
	c.		concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.	
	d.		before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required.	
	e.		In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).	
V.	\boxtimes		IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c): one box)	
	C.F.R.	§ 1.97	ailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 7(c)(1)) or before the mailing date of a Notice of Allowance under 37 1 (See 37 C.F.R. § 1.97(c)(2)).	
	a.		No statement; therefore, a fee in the amount of $$180.00$ as required by 37 C.F.R. $$1.17(p)$.	
	b.		See the statement below. No fee is required.	

VI. STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box) The undersigned hereby states that each item of information contained in the IDS was first cited in any a. communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or b. no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS. Some of the items of information were cited in a communication from a c. foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement. VII. PAYMENT OF FEES (check one box) \boxtimes Payment by credit card Form PTO-2038 in the amount of \$180 required by 37 C.F.R. § 1.17(p) is enclosed for the above-identified fee. Please charge Deposit Account No. 16-1435 in the amount required by 37

C.F.R. § 1.17(p) for the above-indicated fee. A triplicate copy of this paper is

attached.

No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 16-1435.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 16-1435 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17. A duplicate of this sheet is attached for that purpose.

Respectfully submitted,

Cynthia B. Rothschild

Reg. No. 47,040

Date Mailed: March 13, 2007

Attachment(s):

▼ PTO/SB/08A

Reference

X Fee

Other:

Express Mail Certificate No. EV 517 992 808 US

PTO/SB/08A (09-06) Approved for use through 03/31/2007. OMB 0651-0031

U.S. Payoff and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons a

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet of

Substitute for form 1449A/PTO

The state of the s						
Complete if Known						
Application Number	10/077,435					
Filing Date	February 15, 2002					
First Named Inventor	M. Vijay Kumar					
Art Unit	1642					
Examiner Name	Davis, Minh Tam B					
Attorney Docket Number	M0351-268908					

U.S. PATENT DOCUMENTS							
Examiner	Cite No.1	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant		
Initials *		Number - Kind Code ² (if known) MM-DD-YYYY	Olica Document	Passages or Relevant Figures Appear			
		US-					
		US-					
		US-					

FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Date MM-DD-YYYY	Applicant of Cited Document		T⁵	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
		CHAUDHARY, K. et al., "Role of the <i>Bcl-2</i> Gene Family in Prostate Cancer Progression and Its Implications for Therapeutic Intervention," Environmental Health Perspectives, Vol. 107, Supplement 1, February 1999.				

Eveniner	Data	
Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.